期刊文献+

联合检测肿瘤标志物鉴别良恶性胸水的临床价值 被引量:6

暂未订购
导出
摘要 目的探讨联合检测肿瘤标志物鉴别良恶性胸水的临床价值。方法对62例肺癌患者、67例肺部良性疾病患者,采用电化学免疫分析法检测胸水CEA、CA15-3、CA125水平,采用化学发光免疫分析法检测SF水平。结果肺癌组CEA、CA15-3、CA125、SF水平显著高于非肺癌组(P<0.01),4种肿瘤标志物联合检测的敏感性和准确性显著提高。结论胸水CEA、CA15-3、CA125、SF联合检测能提高肺癌诊断的敏感性和准确性,对良恶性胸水的鉴别有较大意义。
作者 黄程勇 沈菁
出处 《福建医药杂志》 CAS 2009年第4期99-100,共2页 Fujian Medical Journal
  • 相关文献

参考文献5

二级参考文献21

  • 1梅同华,徐小杰.四项肿瘤标志物测定对癌性、结核性胸腔积液的鉴别诊断价值[J].重庆医科大学学报,2004,29(6):814-816. 被引量:11
  • 2刘晨梅,侯敏,张连祥,蔡忠.肺癌患者血清和胸水中肿瘤标志物联合检测的意义[J].临床检验杂志,2005,23(2):150-150. 被引量:19
  • 3孙耕耘.胸腔积液的诊断与治疗进展[J].临床肺科杂志,2005,10(2):141-143. 被引量:78
  • 4[1]Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Research, 2001, 21 (4) :3085
  • 5[2]Niklinski J, Furman M, Burzyowski T. Preoperative CYFRA21-1 level as aprognostic in resected primary squamous cell lung cancer. B J Cancer, 1996, 74:956
  • 6[3]Antonio LP, Antonio JT, Marisa M. Quantitative analysis of CEA, SCC, CA125, and CA50 cytosolic content in NSCLC.Cancer, 1996, 73 (9) :2305
  • 7[4]Jan K, Ewa W, Andrzej R. C RA21-1, TPA, TPS, SCC and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Research,2000, 20:5035
  • 8[5]J Watine. Prognostic evaluation of primarynon-small cell lung carcinoma patients usingbiological fluid varibles. Scand J Clin Lab Invest, 2000, 60:259
  • 9[6]Kulpa J, Wojcik E, Reinfuss M. Carcinoembryonic antigen,squamous cell carcinoma antigen, CYFRA 21-1, and neuronspecific enolase in squamous cell lung cancer patients. Clinical Chemistry, 2002, 48 (11) :1931
  • 10[7]DiezM, CerdanFJ, Ortega MD. Evaluation ofserum CA125 as a tumor markerin NSCLC. Cancer, 1991, 67:150

共引文献56

同被引文献20

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部